In today’s fast-paced experience economy, pharma companies can no longer rely on static displays and outdated engagement ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

Novartis has shared positive results from a phase 3b study of Fabhalta (iptacopan) in a new population of patients with the ...

Last month, the ISPOR annual meeting in Montreal was brimming with opportunities to explore the latest developments and ...

Medscape Education, a global leader in healthcare education, proudly announces the official launch of its Center of ...

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the US Food and Drug Administration (FDA) ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...

Muscular dystrophy refers to a group of rare, genetic, progressive diseases that primarily affect the body’s muscles, causing ...

Alongside the data in PsA, UCB will present at EULAR new results demonstrating that Bimzelx delivered sustained clinical ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

The US Food and Drug Administration (FDA) has approved Nuvation Bio’s Ibtrozi (taletrectinib) to treat adults with a rare and ...